Last reviewed · How we verify

Depomed — Portfolio Competitive Intelligence Brief

Depomed pipeline: 3 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Gabapentin Extended Release Gabapentin Extended Release marketed
Diclofenac Potassium for Oral Solution Diclofenac Potassium for Oral Solution marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Rheumatology
Zipsor® Zipsor® marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2 (cyclooxygenase enzymes) Pain Management / Rheumatology
Gabapentin Extended Release tablets Gabapentin Extended Release tablets phase 3 Anticonvulsant / Analgesic Alpha-2-delta subunit of voltage-gated calcium channels Neurology / Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Amneal Pharmaceuticals, LLC · 1 shared drug class
  3. Bausch & Lomb Incorporated · 1 shared drug class
  4. Assaf-Harofeh Medical Center · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
  7. Amzell · 1 shared drug class
  8. Actavis Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Depomed:

Cite this brief

Drug Landscape (2026). Depomed — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/depomed. Accessed 2026-06-09.

Related